FIELD: pharmaceuticals.
SUBSTANCE: invention relates to the use of a compound of formula (Ib') or a pharmaceutically acceptable salt thereof for the treatment of cancer selected from gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer and liver cancer in a patient, wherein the said patient does not have clinically detectable metastases or wherein the said patient has clinically detectable metastases and the said compound of formula (Ib') is not directly directed against metastatic invasion, the said compound being 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinoline-2- amine.
EFFECT: obtaining quinoline derivatives for use in the treatment or prevention of cancer.
6 cl, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| BIOMARKERS AND APPLICATIONS IN TREATING VIRAL INFECTIONS, INFLAMMATIONS OR CANCER | 2019 |
|
RU2820481C2 |
| DRUG DELIVERY SYSTEMS BASED ON MAYTANSINOID | 2018 |
|
RU2783076C2 |
| COMBINATION THERAPY USING DIARYL MACROCYCLIC COMPOUNDS | 2018 |
|
RU2784853C2 |
| METHOD OF TREATING CANCER USING A COMBINATION OF CHK1 AND ATR INHIBITORS | 2015 |
|
RU2736219C2 |
| BENZO[b]THIOPHENE STING AGONISTS FOR TREATMENT OF CANCER | 2018 |
|
RU2771811C2 |
| BENZIMIDAZOLES USED AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2415853C2 |
| ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | 2011 |
|
RU2611437C2 |
| COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARING THE COMPOUNDS AND THEIR USE AS ATR KINASE INHIBITORS | 2019 |
|
RU2806857C2 |
| PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS TAM AND MET KINASE INHIBITORS | 2019 |
|
RU2773611C1 |
| REDUCTION OF TUMOR MASS BY INJECTING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | 2017 |
|
RU2745195C2 |
